Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Microscopically confirmed P.falciparum infection~* Age \>18 years~* Able to tolerate oral therapy~* Able to give informed consent~Exclusion Criteria:~* Fulfillment of WHO criteria for severe/cerebral malaria~* Prior treatment with any thiazolidinedione~* Allergy to rosiglitazone~* History of diabetes mellitus~* History of severe/decompensated liver disease~* ALT level \>2.5 times normal~* Current treatment for congestive heart failure~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 (Type: PLACEBO_COMPARATOR): None
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).